Atropine 0.01% Eye Drops for Myopia Control in American Children: A Multiethnic Sample Across Three US Sites

Larkin, Gregory Luke; Tahir, Alifiya; Epley, K. David; Beauchamp, Cynthia L.; Tong, John T.; Clark, Robert A.

doi:10.1007/s40123-019-00217-w

Cited by 44 publications

(48 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent 2-year follow-up observation [16] in children in the United States found that 0.01% atropine could effectively control the progression of myopia. A meta-analysis [17] published last year veri ed the effect of 0.01% atropine on myopia, but it did not compare with other doses.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Atropine to Control Myopia Progression: A Systematic Review and Meta-analysis

Zhao¹,

Cai²,

Ding

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The effect and safety of atropine on delaying the progression of myopia has been extensively studied, but its optimal effect dose is still unclear. Therefore, the purpose of this meta-analysis is to systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia, and to explore the relationship between the dose of atropine and the effect of controlling the progression of myopia. Methods: This work was done through the data search from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of these included studies. In addition, a meta-analysis was performed using Revman5.3 software. Results: A total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated greater in the atropine treatment group than the control group, with MD = -0.80, 95% CI (-0.94, -0.66) during the whole observation period. There was a statistical difference between 0.05%, 0.5%, and 1.0% atropine (P = 0.004). In addition, less axial elongation was showed, with MD = -0.26, 95% CI (-0.33, -0.18) during the whole observation period. Conclusion: The effect of atropine in controlling the progression of myopia was dose related. A 0.05% atropine was likely to be the optimal dose.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Atropine to Control Myopia Progression: A Systematic Review and Meta-analysis

Zhao¹,

Cai²,

Ding

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Myopia control has been a hotspot worldwide, especially in East Asia. To date, various methods have been used for myopia control, such as orthokeratology [10,11], soft contact lenses [12,13] and low-dose atropine [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Visual quality of juvenile myopes wearing multifocal soft contact lenses

et al. 2020

View full text Add to dashboard Cite

Background: It is unclear whether multifocal soft contact lenses (MFSCLs) affect visual quality when they are used for myopia control in juvenile myopes. The aim of this study was, therefore, to investigate the effect of MFSCLs on visual quality among juvenile myopia subjects. Methods: In a prospective, intervention study, thirty-three juvenile myopes were enrolled. Visual perception was assessed by a quality of vision (QoV) questionnaire with spectacles at baseline and after 1 month of MFSCL wear. At the one-month visit, the high (96%) contrast distance visual acuity (distance HCVA) and low (10%) contrast distance visual acuity (distance LCVA) were measured with single vision spectacle lenses, single vision soft contact lenses (SVSCLs) and MFSCLs in a random order. Wavefront aberrations were measured with SVSCLs, with MFSCLs, and without any correction. Results: Neither distance HCVA (p > 0.05) nor distance LCVA (p > 0.05) revealed any significant difference between MFSCLs, SVSCLs and single vision spectacle lenses. The overall score (the sum of ten symptoms) of the QoV questionnaire did not show a statistically significant difference between spectacles at baseline and after 1 month of MFSCL wear (p = 0.357). The results showed that the frequency (p < 0.001), severity (p = 0.001) and bothersome degree (p = 0.016) of halos were significantly worse when wearing MFSCLs than when wearing single vision spectacle lenses. In contrast, the bothersome degree caused by focusing difficulty (p = 0.046) and the frequency of difficulty in judging distance or depth perception (p = 0.046) were better when wearing MFSCLs than when wearing single vision spectacle lenses. Compared with the naked eye, MFSCLs increased the total aberrations (p < 0.001), higher-order aberrations (p < 0.001), trefoil (p = 0.023), coma aberrations (p < 0.001) and spherical aberrations (SA) (p < 0.001). Compared with the SVSCLs, MFSCLs increased the total aberrations (p < 0.001), higher-order aberrations (p < 0.001), coma aberrations (p < 0.001) and SA (p < 0.001). The direction of SA was more positive (p < 0.001) with the MFSCLs and more negative (p = 0.001) with the SVSCLs compared with the naked eye. Conclusions: Wearing MFSCLs can provide satisfactory corrected visual acuity (both distance HCVA and distance LCVA). Although the lenses increased the aberrations, such as total aberrations and higher-order aberrations, there were few adverse effects on the distance HCVA, distance LCVA and visual perception after 1 month of MFSCL use.

show abstract

“…A recent 2-year follow-up observation [19] in children in the United States found that 0.01% atropine could effectively control the progression of myopia. A meta-analysis [20] published last year verified the effect of 0.01% atropine on myopia, but it did not compare with other doses.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Atropine to Control Myopia Progression: a Systematic Review and Meta-analysis

Zhao¹,

Cai²,

Ding

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: To systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia.Methods: This work was done through the data search from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of these included studies. In addition, a meta-analysis was performed using Revman5.3 software.Results: A total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated in the atropine treatment group, with MD = -0.80, 95% CI (-0.94, -0.66). There was a statistical difference between 0.05%, 0.5%, and 1.0% atropine (P = 0.004). In addition, axial elongation was slowed, with MD = -0.26, 95% CI (-0.33, -0.18).Conclusion: The effect of atropine in controlling the progression of myopia was dose-dependent. A 0.05% atropine was most likely to be the optimal dose.

show abstract

Atropine 0.01% Eye Drops for Myopia Control in American Children: A Multiethnic Sample Across Three US Sites

Cited by 44 publications

References 17 publications

Efficacy and Safety of Atropine to Control Myopia Progression: A Systematic Review and Meta-analysis

Efficacy and Safety of Atropine to Control Myopia Progression: A Systematic Review and Meta-analysis

Visual quality of juvenile myopes wearing multifocal soft contact lenses

Efficacy and Safety of Atropine to Control Myopia Progression: a Systematic Review and Meta-analysis

Contact Info

Product

Resources

About